Details for New Drug Application (NDA): 021698
✉ Email this page to a colleague
The generic ingredient in ZANTAC 150 is ranitidine hydrochloride. There are forty-three drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the ranitidine hydrochloride profile page.
Summary for 021698
Tradename: | ZANTAC 150 |
Applicant: | Chattem Sanofi |
Ingredient: | ranitidine hydrochloride |
Patents: | 0 |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 150MG BASE | ||||
Approval Date: | Aug 31, 2004 | TE: | RLD: | Yes |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 150MG BASE | ||||
Approval Date: | Mar 13, 2007 | TE: | RLD: | Yes |
Expired US Patents for NDA 021698
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Chattem Sanofi | ZANTAC 150 | ranitidine hydrochloride | TABLET;ORAL | 021698-002 | Mar 13, 2007 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription